Comprehensive insight into immune regulatory mechanisms and vascular wall determinants of atherogenesis - Emerging perspectives of immunomodulation

Archives of Medical Science

Volumn 9, Issue 1, 2013, Pages 159-165

  Chalubinski, MacIej ^a   Wojdan, Katarzyna ^a   Dorantowicz, Roksana ^a   Jackowska, Paulina ^a   Gorzelak, Paulina ^a   Broncel, Marlena ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Atherosclerosis; Endothelium; Immunoregulation; Regulatory T cells; Th17 cells

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTICLE; ATHEROGENESIS; BACTERIUM; BLOOD VESSEL WALL; CELLULAR IMMUNITY; DRUG MECHANISM; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; NONHUMAN; REGULATORY T LYMPHOCYTE; TH1 TH2 BALANCE; TH17 CELL;

EID: 84874921049     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2013.33355     Document Type: Article

References (57)

1. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol 2011; 12: 204-12.
2. Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci U S A 1995; 92: 3893-7.
3. Hansson GK, Holm J, Jonasson L. Detection of activated T lymphocytes in the human atherosclerotic plaque. Am J Pathol 1989; 135: 169-75.
4. Buono C, Come CE, Stavrakis G, Maguire GF, Connelly PW, Lichtman AH. Influence of interferon-gamma on the extent and phenotype of diet-induced atherosclerosis in the LDLR-deficient mouse. Arterioscler Thromb Vasc Biol 2003; 23: 454-60.
5. Whitman SC, Ravisankar P, Daugherty A. IFN-gamma deficiency exerts gender-specific effects on atherogenesis in apolipoprotein E-/- mice. J Interferon Cytokine Res 2002; 22: 661-70.
6. Whitman SC, Ravisankar P, Elam H, Daugherty A. Exo - genous interferon-gamma enhances atherosclerosis in apolipoprotein E-/- mice. Am J Pathol 2000; 157: 1819-24.
7. Buono C, Binder CJ, Stavrakis G, Witztum JL, Glimcher LH, Lichtman AH. T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses. Proc Natl Acad Sci U S A 2005; 102: 1596-601.
8. McLaren JE, Ramji DP. Interferon gamma: a master regulator of atherosclerosis. Cytokine Growth Factor Rev 2009; 20: 125-35.
9. Binder CJ, Hartvigsen K, Chang MK, et al. IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J Clin Invest 2004; 114: 427-37.
10. Horkko S, Bird DA, Miller E, et al. Monoclonal auto - antibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J Clin Invest 1999; 103: 117-28.
11. Leskinen MJ, Kovanen PT, Lindstedt KA. Regulation of smooth muscle cell growth, function and death in vitro by activated mast cells: a potential mechanism for the weakening and rupture of atherosclerotic plaques. Biochem Pharmacol 2003; 66: 1493-8.
12. Davenport P, Tipping PG. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am J Pathol 2003; 163: 1117-25.
13. King VL, Szilvassy SJ, Daugherty A. Interleukin-4 defi - ciency decreases atherosclerotic lesion formation in a sitespecific manner in female LDL receptor-/- mice. Arterioscler Thromb Vasc Biol 2002; 22: 456-61.
14. Mor A, Planer D, Luboshits G, et al. Role of naturally occurring CD4+ CD25+ regulatory T cells in experimental atherosclerosis. Arterioscler Thromb Vasc Biol 2007; 27: 893-900.
15. Ait-Oufella H, Salomon BL, Potteaux S, et al. Natural regulatory T cells control the development of athero - sclerosis in mice. Nat Med 2006; 12: 178-80.
16. Mieczkowska J, Mosiewicz J, Barud W, Kwasniewski W. Changes in the activity of connective tissue matrix enzymes in the metabolic syndrome. Arch Med Sci 2011; 7: 634-41.
17. de Boer OJ, van der Meer JJ, Teeling P, van der Loos CM, van der Wal AC. Low numbers of FOXP3 positive re - gulatory T cells are present in all developmental stages of human atherosclerotic lesions. PLoS One 2007; 2: e779.
18. Mor A, Luboshits G, Planer D, Keren G, George J. Altered status of CD4(+)CD25(+) regulatory T cells in patients with acute coronary syndromes. Eur Heart J 2006; 27: 2530-7.
19. Kofler S, Sisic Z, Shvets N, Lohse P, Weis M. Expression of circulatory dendritic cells and regulatory T-cells in patients with different subsets of coronary artery disease. J Cardiovasc Pharmacol 2011; 57: 542-9.
20. Sardella G, De Luca L, Francavilla V, et al. Frequency of naturally-occurring regulatory T cells is reduced in pa - tients with ST-segment elevation myocardial infarction. Thromb Res 2007; 120: 631-4.
21. Ammirati E, Cianflone D, Banfi M, et al. Circulating CD4+CD25hiCD127lo regulatory T-cell levels do not reflect the extent or severity of carotid and coronary athero - sclerosis. Arterioscler Thromb Vasc Biol 2010; 30: 1832-41.
22. Smith E, Prasad KM, Butcher M, et al. Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice. Circulation 2010; 121: 1746-55.
23. Butcher MJ, Gjurich BN, Phillips T, Galkina EV. The IL-17A/ IL-17RA axis plays a proatherogenic role via the regulation of aortic myeloid cell recruitment. Circ Res 2012; 110: 675-87.
24. Usui F, Kimura H, Ohshiro T, et al. Interleukin-17 deficiency reduced vascular inflammation and development of atherosclerosis in Western diet-induced apoE-deficient mice. Biochem Biophys Res Commun 2012; 420: 72-7.
25. Eid RE, Rao DA, Zhou J, et al. Interleukin-17 and interferongamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation 2009; 119: 1424-32.
26. Zhao Z, Wu Y, Cheng M, et al. Activation of Th17/Th1 and Th1, but not Th17, is associated with the acute cardiac event in patients with acute coronary syndrome. Athero - sclerosis 2011; 217: 518-24.
27. Liu ZD, Wang L, Lu FH, et al. Increased Th17 cell frequency concomitant with decreased Foxp3+ Treg cell frequency in the peripheral circulation of patients with carotid artery plaques. Inflamm Res 2012; 61: 1155-65.
28. Yang K, Li D, Luo M, Hu Y. Generation of HSP60-specific regulatory T cell and effect on atherosclerosis. Cell Immunol 2006; 243: 90-5.
29. Bielecka-Dabrowa A, Barylski M, Mikhailidis DP, Rysz J, Banach M. HSP 70 and atherosclerosis: protector or activator? Expert Opin Ther Targets 2009; 13: 307-17.
30. den Dekker WK, Cheng C, Pasterkamp G, Duckers HJ. Toll like receptor 4 in atherosclerosis and plaque desta bili - zation. Atherosclerosis 2010; 209: 314-20.
31. Rizzo M, Macario AJ, de Macario EC, et al. Heat shock protein-60 and risk for cardiovascular disease. Curr Pharm Des 2011; 17: 3662-8.
32. Marker T, Sell H, Zillessen P, et al. Heat shock protein 60 as a mediator of adipose tissue inflammation and insulin resistance. Diabetes 2012; 61: 615-25.
33. Ayada K, Yokota K, Kobayashi K, Shoenfeld Y, Matsuura E, Oguma K. Chronic infections and atherosclerosis. Clin Rev Allergy Immunol 2009; 37: 44-8.
34. Jitsuiki K, Yamane K, Nakajima M, et al. Association of Chlamydia pneumoniae infection and carotid intimamedia wall thickness in Japanese Americans. Circ J 2006; 70: 815-9.
35. Tasaki N, Nakajima M, Yamamoto H, et al. Influence of Chlamydia pneumoniae infection on aortic stiffness in healthy young men. Atherosclerosis 2003; 171: 117-22.
36. Taniguchi A, Nishimura F, Murayama Y, et al. Porphyro - monas gingivalis infection is associated with carotid atherosclerosis in non-obese Japanese type 2 diabetic patients. Metabolism 2003; 52: 142-5.
37. Miyauchi S, Maekawa T, Aoki Y, et al. Oral infection with Porphyromonas gingivalis and systemic cytokine profile in C57BL/6.KOR-ApoE(shl) mice. J Periodontal Res 2012; 47: 402-8.
38. Rizzo M, Cappello F, Marfil R, et al. Heat-shock protein 60 kDa and atherogenic dyslipidemia in patients with untreated mild periodontitis: a pilot study. Cell Stress Chaperones 2012; 17: 399-407.
39. Mikhailidis DP, Elisaf M, Rizzo M, et al. "European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol 2011; 9: 533-71.
40. Vizzardi E, Bonadei I, Piovanelli B, et al. Helicobacter pylori and ischemic heart disease. Panminerva Med 2011; 53: 193-202.
41. Izadi M, Fazel M, Sharubandi SH, et al. Helicobacter species in the atherosclerotic plaques of patients with coronary artery disease. Cardiovasc Pathol 2012; 21: 307-11.
42. Blum A, Tamir S, Mualem K, Ben-Shushan RS, Keinan- Boker L, Paritsky M. Endothelial dysfunction is reversible in Helicobacter pylori-positive subjects. Am J Med 2011; 124: 1171-4.
43. Takaoka N, Campbell LA, Lee A, Rosenfeld ME, Kuo CC. Chlamydia pneumoniae infection increases adherence of mouse macrophages to mouse endothelial cells in vitro and to aortas ex vivo. Infect Immun 2008; 76: 510-4.
44. Benagiano M, Munari F, Ciervo A, et al. Chlamydophila pneumoniae phospholipase D (CpPLD) drives Th17 inflam - mation in human atherosclerosis. Proc Natl Acad Sci U S A 2012; 109: 1222-7.
45. Lundberg AM, Hansson GK. Innate immune signals in atherosclerosis. Clin Immunol 2010; 134: 5-24.
46. Schober A. Chemokines in vascular dysfunction and re - modeling. Arterioscler Thromb Vasc Biol 2008; 28: 1950-9.
47. von Hundelshausen P, Weber KS, Huo Y, et al. RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation 2001; 103: 1772-7.
48. Eizawa T, Ikeda U, Murakami Y, et al. Decrease in cir - culating endothelial progenitor cells in patients with stable coronary artery disease. Heart 2004; 90: 685-6.
49. Vasa M, Fichtlscherer S, Aicher A, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001; 89: E1-7.
50. Sata M, Saiura A, Kunisato A, et al. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med 2002; 8: 403-9.
51. Schober A, Karshovska E, Zernecke A, Weber C. SDF- 1alpha-mediated tissue repair by stem cells: a promising tool in cardiovascular medicine? Trends Cardiovasc Med 2006; 16: 103-8.
52. Chalubinski M, Broncel M. Influence of statins on effector and regulatory immune mechanisms and their potential clinical relevance in treating autoimmune disorders. Med Sci Monit 2010; 16: RA245-51.
53. Vasa M, Fichtlscherer S, Adler K, et al. Increase in cir - culating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 2001; 103: 2885-90.
54. Landmesser U, Engberding N, Bahlmann FH, et al. Statininduced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventri - cular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 2004; 110: 1933-9.
55. Mallat Z, Gojova A, Brun V, et al. Induction of a regulatory T cell type 1 response reduces the development of athero - sclerosis in apolipoprotein E-knockout mice. Circulation 2003; 108: 1232-7.
56. van Puijvelde GH, Hauer AD, de Vos P, et al. Induction of oral tolerance to oxidized low-density lipoprotein amelio - rates atherosclerosis. Circulation 2006; 114: 1968-76.
57. Hermansson A, Johansson DK, Ketelhuth DF, Andersson J, Zhou X, Hansson GK. Immunotherapy with tolerogenic apolipoprotein B-100-loaded dendritic cells attenuates atherosclerosis in hypercholesterolemic mice. Circulation 2011; 123: 1083-91.